TLDR
- Oscar Health (OSCR) stock rose ~11% Wednesday after CEO Mark Bertolini purchased 1 million OSCR stock at $11.92 per share.
- The $11.92M transaction was a private placement, not an open-market buy — meaning new stock was issued directly to the CEO.
- Bertolini now holds 10.2M OSCR stock, representing 10.87% ownership of the company.
- OSCR stock had already climbed ~7% Tuesday after the U.S. government confirmed a 2.5% Medicare Advantage reimbursement rate hike for 2027.
- Oscar ended 2025 with $443.2M in net losses but is guiding for 60% revenue growth in 2026, targeting $18.7–$19B.
Get live prices, charts, and KO Scores from KnockoutStocks.com, the data-driven platform ranking every stock by quality and breakout potential.
Oscar Health (OSCR) is trading at $14.43, up $2.21 (+15.29%) on the day as of market open.
Oscar Health CEO Mark Bertolini made headlines this week after buying 1 million OSCR at $11.92 each — a $11.92M personal bet on the health insurer’s turnaround. The stock jumped ~11% Wednesday morning on the news.
The purchase was disclosed in a regulatory filing after Tuesday’s close. Bertolini, who previously served as CEO of Aetna, made the transaction on Monday, April 6.
But the deal wasn’t a typical open-market purchase. The Form 4 filed with the SEC describes it as a private placement — meaning Oscar issued 1 million new shares directly to its CEO at the $11.92 closing price, the same price used that day to withhold stock for tax purposes on newly vested performance units.
The company received $11.92M in fresh capital, while Bertolini’s stake increased to 10.87%, or 10,196,876 shares. Net dilution to other investors was minimal.
What the Numbers Say
Oscar’s 2025 financials paint a company that’s growing fast but still burning cash. Full-year revenue hit $11.7B, up from $9.18B in 2024. Membership reached a record 3.4 million. Net losses for the year came in at $443.2M, with operating losses of $396.4M.
For 2026, the company is guiding for $18.7B–$19B in revenue — roughly 60% year-over-year growth — while targeting a medical-loss ratio of 82.4%–83.4%. Analysts are projecting EPS of $0.77 for 2026, which would mark a turn toward profitability.
That’s a big target to hit. And Bertolini just wrote a personal check suggesting he thinks they will.
Compare that to the bigger players: UnitedHealth Group posted $113.2B in Q4 2025 revenue, up 12.3% year-over-year. Centene and Molina Healthcare grew in single digits. Oscar’s growth rate is in a different league, even if profitability hasn’t arrived yet.
Not a Classic Insider Buy
It’s worth noting what this isn’t. A traditional open-market purchase — where an executive buys at the ask price, absorbs slippage, and risks an immediate loss — is typically seen as the stronger signal. That says: “I like this price, right now.”
A private placement is a different kind of move. Bertolini didn’t wake up and put in a market order. He acquired stock at a pre-set fair market value price, part of a coordinated transaction tied to vesting. The company got cash; he got stock.
Still, Bertolini could have sold his vested shares to cover taxes and walked away with cash. Instead, he chose to own more. At current prices, he holds roughly $125M worth of Oscar stock.
OSCR stock had already gained ~7% on Tuesday after the U.S. government confirmed a 2.5% Medicare Advantage reimbursement hike for 2027 — higher than the prior proposal to keep rates flat.
Oscar’s Q1 2025 earnings are scheduled for May 6 before the market open.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.
